1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
3-D Matrix, Ltd.

3-D Matrix, Ltd.

362.00
JPY
-21.00
(-5.48%)
66.03BMarket Cap
Dec 15Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
5.46
4.75
6.6
28.58
9.95
12.54
22.45
25.27
29.57
38.45
62.61
62.87
91.39
- -
Basic EPS, GAAP
-77.77
-94.89
-114.49
-64.62
-81.26
-97.41
-103.36
-49.65
-37.2
-40.64
-3.49
-22.68
34.89
- -
Free Cash Flow per Basic Share
-87.67
-94.49
-70.1
-88.63
-89.2
-88.77
-73.7
-80.8
-57.26
-76.49
-25.98
-15.65
3.09
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
157.64
297.67
182.87
120.63
91.83
53.93
14.84
37.37
26.62
8.15
4.33
20.09
53.11
- -
Tangible Book Value per Share
140.59
279.35
182.87
120.63
91.83
53.93
14.84
37.37
26.62
8.15
4.33
20.09
53.11
- -
Basic Weighted Avg Shares
20
21
21
22
23
26
30
41
51
60
73
110
119
121
Sales/Revenue/Turnover
107
100
142
616
229
329
672
1,024
1,506
2,314
4,589
6,934
10,886
- -
Operating Margin (%)
-1,416.95
-1,907.34
-1,284.22
-201.42
-819.99
-689.44
-377.2
-258.56
-181.69
-136.48
-46.13
-16.67
12.27
- -
Depreciation Expense
102
123
231
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1,525
-1,995
-2,459
-1,393
-1,866
-2,555
-3,096
-2,013
-1,895
-2,446
-256
-2,501
4,156
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,423.45
-1,999.44
-1,733.95
-226.12
-816.31
-776.82
-460.45
-196.47
-125.79
-105.7
-5.57
-36.07
38.18
- -
Working Capital
2,634
5,795
3,898
2,572
2,177
2,787
1,847
2,702
4,710
4,365
4,255
4,840
6,223
- -
LT Debt
28
14
- -
- -
- -
1,300
1,400
1,050
3,265
3,874
3,874
2,641
- -
- -
Total Equity
3,133
6,382
3,936
2,607
2,202
1,513
473
1,660
1,458
525
353
2,216
6,796
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-58.68
-41.93
-47.67
-42.57
-77.61
-137.53
-311.8
-188.73
-121.55
-246.76
-58.2
-194.69
92.22
- -

Capital Structure

JPY

•

in mil. unless spec.
Jul'25
Apr'26
Jul'27
ST Debt
- -
600
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
91
128
128
Market Capitalization
14,502
66,033
42,106

Working Capital

JPY

•

in mil. unless spec.
Jul'25
Apr'26
Jul'27
Total Current Assets
- -
9,179
- -
Cash, Cash Equivalents & STI
- -
2,831
- -
Accounts Receivable, Net
- -
2,684
- -
Inventories
- -
3,146
- -
Total Current Liabilities
- -
2,956
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
600
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
72.67%
125.02%
206.67%
Free Cash Flow
-5.15%
-28.49%
-121.35%
Net Income, GAAP
56.02%
109.29%
-266.15%
Sales/Revenue/Turnover
77.91%
61.42%
57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
6,934
2026
- -
- -
- -
- -
10,886
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
-22.68
2026
- -
- -
- -
- -
34.89
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Toshihiko Amanuma
Full Time Employees
129
Sector
Health technology
Industry
Medical specialties
Address
Kojimachi HF Building Tokyo TY Japan 102-0083
IPO Date
Oct 24, 2011
Website
3d-matrix.co.jp
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
3-D Matrix, Ltd. (7777.T) develops, manufactures, and sells self-assembling peptide-based medical products for surgery, regenerative medicine, and drug delivery systems; its core offerings include PuraStat, a synthetic hemostatic gel in prefilled syringes for managing bleeding in gastrointestinal endoscopic procedures and reducing delayed bleeds post-submucosal dissection; PuraBond, a transparent hemostatic gel for vascular anastomoses and parenchymal bleeding in solid organs; and PuraSinus for sinus applications, along with associated accessories for endoscopic and laparoscopic use. Founded in 2004 as an MIT spinoff and headquartered in Tokyo, Japan, the company operates globally through subsidiaries and offices in the United States, United Kingdom, Australia, Singapore, the Netherlands, and France, targeting healthcare providers, surgeons, and research institutions across Americas, Europe, Middle East, and Asia. Recent developments include FDA 510(k) clearance for PuraStat-GI in gastrointestinal endoscopy and Japanese National Health Insurance listing in 2021; formation of 3-D Matrix Medical Technology Pty Ltd in Australia for direct sales in 2019; and a private placement of series 9th unsecured convertible bonds raising ¥1.103 billion from CVI Investments, Inc. in June 2025 to support growth.